MX2015008911A - Composicion farmaceutica con biodisponibilidad mejorada. - Google Patents
Composicion farmaceutica con biodisponibilidad mejorada.Info
- Publication number
- MX2015008911A MX2015008911A MX2015008911A MX2015008911A MX2015008911A MX 2015008911 A MX2015008911 A MX 2015008911A MX 2015008911 A MX2015008911 A MX 2015008911A MX 2015008911 A MX2015008911 A MX 2015008911A MX 2015008911 A MX2015008911 A MX 2015008911A
- Authority
- MX
- Mexico
- Prior art keywords
- improved bioavailability
- pharmaceutical composition
- fluorophenyl
- chloro
- compounds
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2813—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/282—Organic compounds, e.g. fats
Abstract
La invención se refiere a dispersiones sólidas de compuestos de baja solubilidad acuosa, en particular el Compuesto A tal como se da a conocer en la presente memoria, formado mediante coprecipitación de solventes o secado mediante pulverización, resultando en una biodisponibilidad, seguridad y tolerabilidad mejoradas de dichos compuestos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361755074P | 2013-01-22 | 2013-01-22 | |
PCT/EP2014/050974 WO2014114575A1 (en) | 2013-01-22 | 2014-01-20 | Pharmaceutical composition with improved bioavailability |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2015008911A true MX2015008911A (es) | 2015-10-22 |
Family
ID=50023547
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2015008911A MX2015008911A (es) | 2013-01-22 | 2014-01-20 | Composicion farmaceutica con biodisponibilidad mejorada. |
Country Status (24)
Country | Link |
---|---|
US (2) | US9427427B2 (es) |
EP (1) | EP2948141A1 (es) |
JP (1) | JP6192244B2 (es) |
KR (1) | KR101737250B1 (es) |
CN (3) | CN104936589A (es) |
AR (1) | AR094548A1 (es) |
AU (1) | AU2014210103B2 (es) |
BR (1) | BR112015015758B1 (es) |
CA (1) | CA2892025C (es) |
CL (1) | CL2015001649A1 (es) |
CR (1) | CR20150287A (es) |
EA (1) | EA028009B1 (es) |
HK (1) | HK1211217A1 (es) |
IL (1) | IL239657B (es) |
MA (1) | MA38289A1 (es) |
MX (1) | MX2015008911A (es) |
MY (1) | MY192032A (es) |
NZ (1) | NZ708272A (es) |
PE (1) | PE20151335A1 (es) |
PH (1) | PH12015501620B1 (es) |
SG (1) | SG11201504499VA (es) |
UA (1) | UA116004C2 (es) |
WO (1) | WO2014114575A1 (es) |
ZA (1) | ZA201504187B (es) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20160138307A (ko) | 2014-04-15 | 2016-12-02 | 에프. 호프만-라 로슈 아게 | 약학적으로 활성인 화합물의 고체 형태 |
PT107846B (pt) * | 2014-08-01 | 2019-03-22 | Hovione Farm S A | Produção de nano- partículas de dispersões sólidas amorfas por co-precipitação controlada |
AU2015358493B2 (en) * | 2014-12-05 | 2021-05-06 | Aragon Pharmaceuticals, Inc. | Anticancer compositions |
CA2969675C (en) | 2014-12-05 | 2023-06-06 | Aragon Pharmaceuticals, Inc. | Anticancer compositions |
CA2987867C (en) * | 2015-06-09 | 2023-06-27 | Capsugel Belgium Nv | Formulations to achieve rapid dissolution of drug from spray-dried dispersions in capsules |
GB201609222D0 (en) | 2016-05-25 | 2016-07-06 | F2G Ltd | Pharmaceutical formulation |
CN109152745A (zh) * | 2017-04-21 | 2019-01-04 | 株式会社生物研究 | 利用脂质作为研磨工序中的润滑剂的制备活性物质纳米粒子的方法 |
US11304945B2 (en) * | 2017-07-04 | 2022-04-19 | Jiangsu Hengrui Medicine Co., Ltd. | Pharmaceutical composition and method for preparing same |
CN112004529B (zh) | 2018-04-06 | 2023-08-08 | 比利时胶囊公司 | 包含聚[(甲基丙烯酸甲酯)-共-(甲基丙烯酸)]的低纵横比颗粒的喷雾干燥方法 |
WO2019213106A1 (en) | 2018-04-30 | 2019-11-07 | Teva Pharmaceuticals International Gmbh | Solid state forms of idasanutlin |
TW202043225A (zh) * | 2019-01-25 | 2020-12-01 | 英屬開曼群島商百濟神州有限公司 | B-raf激酶二聚體抑制劑之穩定固體分散體、製備方法及其用途 |
US11819503B2 (en) | 2019-04-23 | 2023-11-21 | F2G Ltd | Method of treating coccidioides infection |
JP2022534610A (ja) * | 2019-05-31 | 2022-08-02 | 江蘇恒瑞医薬股▲ふん▼有限公司 | 固体分散体およびその調製方法 |
MX2022003347A (es) * | 2019-09-23 | 2022-04-11 | Bionomics Ltd | Formulaciones terapeuticas y usos de las mismas. |
KR20220109430A (ko) * | 2019-12-02 | 2022-08-04 | 아스트라제네카 아베 | 6-(2-클로로-6-메틸피리딘-4-일)-5-(4-플루오로페닐)-1,2,4-트리아진-3-아민의 고체 약학 제형 |
CN114929203A (zh) * | 2019-12-20 | 2022-08-19 | 英特维特国际股份有限公司 | 分散在聚合物基质中的吡唑化合物的药物组合物 |
TW202211911A (zh) * | 2020-06-05 | 2022-04-01 | 美商應用材料股份有限公司 | 經塗佈的藥物組成物及製備彼之方法 |
CN112022812B (zh) * | 2020-11-03 | 2021-01-29 | 上海亚盛医药科技有限公司 | 一种包含杂环类化合物的组合物、其制备方法和应用 |
EP4119128A1 (en) * | 2021-07-13 | 2023-01-18 | Dr. Falk Pharma Gmbh | Pharmaceutical composition for the oral administration of poorly soluble drugs comprising an amorphous solid dispersion |
WO2024025609A1 (en) * | 2022-07-26 | 2024-02-01 | Wellstat Therapeutics Corporation | Uridine triacetate amorphous formulation and uses thereof |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5399363A (en) | 1991-01-25 | 1995-03-21 | Eastman Kodak Company | Surface modified anticancer nanoparticles |
GB9511220D0 (en) | 1995-06-02 | 1995-07-26 | Glaxo Group Ltd | Solid dispersions |
DE69726729T2 (de) | 1996-05-20 | 2004-12-02 | Janssen Pharmaceutica N.V. | Fungizide mittel mit verbesserter bioverfügbarkeit |
SE9700655L (sv) | 1997-02-25 | 1998-05-11 | Neste Oy | Förfarande för framställning av ftalsyraanhydrid |
US6350786B1 (en) | 1998-09-22 | 2002-02-26 | Hoffmann-La Roche Inc. | Stable complexes of poorly soluble compounds in ionic polymers |
MXPA01005884A (es) | 1998-12-11 | 2002-04-24 | Pharmasolutions Inc | Composiciones auto-emulsionantes para medicamentos escasamente solubles en agua. |
EP1027885B1 (en) | 1999-02-09 | 2008-07-09 | Pfizer Products Inc. | Basic drug compositions with enhanced bioavailability |
US6057289A (en) | 1999-04-30 | 2000-05-02 | Pharmasolutions, Inc. | Pharmaceutical composition comprising cyclosporin in association with a carrier in a self-emulsifying drug delivery system |
HUP0303700A3 (en) | 2000-07-17 | 2006-07-28 | Astellas Pharma Inc Chuo Ku | Pharmaceutical composition improved in peroral absorbability |
HUP0301487A2 (hu) | 2000-10-31 | 2003-11-28 | Boehringer Ingelheim Pharmaceuticals, Inc. | Piranon proteáz inhibitorok orális adagolású önemulgeáló formulációi |
EP1543841A4 (en) | 2002-08-15 | 2011-03-16 | Yunqing Liu | SOLID PHARMACEUTICAL NANO FORMULATION AND MANUFACTURING METHOD THEREFOR |
US7438261B2 (en) | 2004-09-09 | 2008-10-21 | David R. Porter | Stratospheric balloon utilizing electrostatic inflation of walls |
AU2007226984B2 (en) | 2006-03-20 | 2013-02-21 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions |
US8354444B2 (en) * | 2008-09-18 | 2013-01-15 | Hoffmann-La Roche Inc. | Substituted pyrrolidine-2-carboxamides |
MX2011008303A (es) * | 2009-04-03 | 2011-11-29 | Plexxikon Inc | Composiciones del acido propano-1-sulfonico {3-[5-(4-cloro-fenil)- 1h-pirrolo [2,3-b]-piridina-3-carbonil]-2,4-difluoro-fenil}-amida y el uso de las mismas. |
CN102871950B (zh) * | 2011-07-15 | 2016-04-20 | 上海睿智化学研究有限公司 | 一种熊果酸固体分散体及其制备方法 |
US20130245089A1 (en) * | 2012-03-19 | 2013-09-19 | Hoffmann-La Roche Inc. | Method for administration |
US20140128431A1 (en) * | 2012-04-03 | 2014-05-08 | Hoffmann-Laroche Inc. | Pharmaceutical composition with improved bioavailability, safety and tolerability |
-
2014
- 2014-01-20 CN CN201480005646.7A patent/CN104936589A/zh active Pending
- 2014-01-20 SG SG11201504499VA patent/SG11201504499VA/en unknown
- 2014-01-20 CN CN202011052471.9A patent/CN112370427A/zh active Pending
- 2014-01-20 NZ NZ708272A patent/NZ708272A/en not_active IP Right Cessation
- 2014-01-20 CA CA2892025A patent/CA2892025C/en active Active
- 2014-01-20 KR KR1020157019822A patent/KR101737250B1/ko active IP Right Grant
- 2014-01-20 UA UAA201507997A patent/UA116004C2/uk unknown
- 2014-01-20 JP JP2015553108A patent/JP6192244B2/ja active Active
- 2014-01-20 WO PCT/EP2014/050974 patent/WO2014114575A1/en active Application Filing
- 2014-01-20 EA EA201591276A patent/EA028009B1/ru not_active IP Right Cessation
- 2014-01-20 CN CN202011052449.4A patent/CN112353762A/zh active Pending
- 2014-01-20 MY MYPI2015702350A patent/MY192032A/en unknown
- 2014-01-20 AU AU2014210103A patent/AU2014210103B2/en active Active
- 2014-01-20 EP EP14701504.4A patent/EP2948141A1/en active Pending
- 2014-01-20 MX MX2015008911A patent/MX2015008911A/es active IP Right Grant
- 2014-01-20 PE PE2015001370A patent/PE20151335A1/es unknown
- 2014-01-20 BR BR112015015758-0A patent/BR112015015758B1/pt active IP Right Grant
- 2014-01-21 US US14/159,679 patent/US9427427B2/en active Active
- 2014-01-22 AR ARP140100191A patent/AR094548A1/es unknown
-
2015
- 2015-05-28 CR CR20150287A patent/CR20150287A/es unknown
- 2015-06-10 ZA ZA2015/04187A patent/ZA201504187B/en unknown
- 2015-06-12 CL CL2015001649A patent/CL2015001649A1/es unknown
- 2015-06-25 IL IL239657A patent/IL239657B/en active IP Right Grant
- 2015-07-22 PH PH12015501620A patent/PH12015501620B1/en unknown
- 2015-07-23 MA MA38289A patent/MA38289A1/fr unknown
- 2015-12-08 HK HK15112066.7A patent/HK1211217A1/xx unknown
-
2016
- 2016-07-01 US US15/200,419 patent/US10034854B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12015501620A1 (en) | Pharmaceutical composition with improved bioavailability | |
WO2012168430A3 (en) | Polypeptides | |
WO2015013330A3 (en) | Ophthalmic uses of toxin-based therapeutic peptides and pharmaceutical compositions thereof | |
WO2015051030A3 (en) | Stabilized polypeptides and uses thereof | |
CL2015001358A1 (es) | Potenciadores del cftr deuterados | |
WO2016149401A3 (en) | Piperazine carbamates and methods of making and using same | |
AU2018256493A1 (en) | Peptide Compositions | |
WO2010065709A3 (en) | Hydroxamic acid derivatives, preparation and therapeutic uses thereof | |
EA201690287A1 (ru) | 1,4-дизамещенные аналоги пиридазин хинолина и способы лечения состояний, связанных с smn-дефицитом | |
NZ626505A (en) | Substituted pyrrolidine-2-carboxamides | |
MX2021001169A (es) | Formas sólidas de ácido {[5-(3-clorofenil)-3-hidroxipiridin-2-carb onil]amino}acético, composiciones, y usos de las mismas. | |
EP4309735A3 (en) | Pharmaceutical composition of s-ketamine hydrochloride | |
WO2015177175A3 (en) | Novel specific-binding polypeptides and uses thereof | |
EA201590953A1 (ru) | Пирролидиновые модуляторы gpr40 | |
EA201491613A1 (ru) | Катионные полимеры на основе гликогена | |
WO2014076321A8 (en) | Novel specific-binding polypeptides and uses thereof | |
IN2014MN02236A (es) | ||
EA201891804A1 (ru) | Тетрациклиновые соединения | |
WO2016209978A3 (en) | Thiol-ene based peptide stapling and uses thereof | |
EA201591795A1 (ru) | Бицикло[2.2.1]-кислоты в качестве модуляторов рецептора gpr120 | |
EA201590601A1 (ru) | Применение pedf-производных полипептидов для лечения остеоартрита | |
WO2017093810A3 (en) | Composition for intraoral delivery of biologically active peptides and proteins | |
MX2017010666A (es) | Acido (2r,4r)-5-(5'-cloro-2'-fluorobifenil-4-il)-2-hidroxi-4-[(5-m etiloxazol-2-carbonil)amino]pentanoico. | |
MX2014009617A (es) | Polimorfos de n-(2-metoxibenzoil)-4-[(metilaminocarbonil)amino]ben cenosulfonamida. | |
NZ700467A (en) | Treatments suitable for malassezia infections |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |